Names that match “Santander Consumer USA Inc”
1,837 documents found
nett I, 274 F.Supp.2d at 104. Proximate
document IMAGES-004-HOUSE_OVERSIGHT_017891.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
826
nett I, 274 F.Supp.2d at 104. Proximate
cause will support this connection. See
Furst Nationurde Bank v. Gelt Funding
Corp., 27 F.3d 768, 769 (2d Cir.1994)
(“Central to the notion of proximate cause
is the idea that a person is not liable to all
those who may have been injur...
1533, 1537 (S.D.N.Y.1983) (holding corre
document IMAGES-004-HOUSE_OVERSIGHT_017885.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
820
1533, 1537 (S.D.N.Y.1983) (holding corre-
spondent banking relationships insufficient
to create general personal jurisdiction).
NCB offers its customers the opportunity
to open accounts directly with United
States-based securities broker-dealers, but
NCB does not act as a br...
Bellingham, Washington
document IMAGES-008-HOUSE_OVERSIGHT_024794.txt House Oversight Committee — Epstein Estate Records (Nov 2025)
Or
>
A
“Bw
Plan
fon on
RO RUBICON
. . ORGANICS
Rubicon Organics
Bellingham, Washington
www.rubiconorganics.com
Rubicon Organics is a licensed cannabis culti-
vator specializing in the growing, processing,
packaging and marketing of cannabis. The com-
pany is developing greenho...
Paul J. Set Theory and the Continuum Hypothesis. Dover Publications Inc
document Cohen House Oversight Committee — Epstein Estate Records (Nov 2025)
Paul J. Set Theory and the Continuum Hypothesis. Dover Publications Inc.
and/or was involved in Novamente LLC and Webmind Inc
document involved with the OpenCog project House Oversight Committee — Epstein Estate Records (Nov 2025)
and/or was involved in Novamente LLC and Webmind Inc.
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
document Acadia Phamaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
document Ambit Biosciences House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%
Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%
document Audax Health Solutions House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
document Chimerix House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%
document Epizyme House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%
Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM
document Glumetrics House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM
Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%
document Intercept Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%
Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%
document Kalidex Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%
Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%
document MEI Pharma House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%
Inc. Therapeutics 2009 11.0 - - - - - NM
document Presidio Pharmaceuticals House Oversight Committee — Epstein Estate Records (Nov 2025)
Inc. Therapeutics 2009 11.0 - - - - - NM